Cargando…

Optimizing Phosphopeptide Structures That Target 14-3-3ε in Cutaneous Squamous Cell Carcinoma

14-3-3ε is involved in various types of malignancies by increasing cell proliferation, promoting cell invasion or inhibiting apoptosis. In cutaneous squamous cell carcinoma (cSCC), 14-3-3ε is over expressed and mislocalized from the nucleus to the cytoplasm where it interacts with the cell division...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamayirese, Seraphine, Maity, Sibaprasad, Dieckman, Lynne M., Hansen, Laura A., Lovas, Sándor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592926/
https://www.ncbi.nlm.nih.gov/pubmed/37873379
http://dx.doi.org/10.1101/2023.10.03.560749
_version_ 1785124365535281152
author Kamayirese, Seraphine
Maity, Sibaprasad
Dieckman, Lynne M.
Hansen, Laura A.
Lovas, Sándor
author_facet Kamayirese, Seraphine
Maity, Sibaprasad
Dieckman, Lynne M.
Hansen, Laura A.
Lovas, Sándor
author_sort Kamayirese, Seraphine
collection PubMed
description 14-3-3ε is involved in various types of malignancies by increasing cell proliferation, promoting cell invasion or inhibiting apoptosis. In cutaneous squamous cell carcinoma (cSCC), 14-3-3ε is over expressed and mislocalized from the nucleus to the cytoplasm where it interacts with the cell division cycle 25 A (CDC25A) and suppresses apoptosis. Hence inhibition of the 14-3-3ε - CDC25A interaction is an attractive target for promoting apoptosis in cSCC. In this work, we optimized the structure of our previously designed inhibitor of 14-3-3ε – CDC25A interaction, pT, a phosphopeptide fragment corresponding to one of the two binding regions of CDC25A to 14-3-3ε. Starting from pT, we developed peptide analogs that bind 14-3-3ε with nanomolar affinities. Peptide analogs were designed by shortening the pT peptide, and introducing modifications at position 510 of the pT(502–510) analog. Both molecular dynamics (MD) simulations and biophysical methods were used to determine peptides binding to 14-3-3ε. Shortening the pT peptide from 14 to 9 amino acid residues resulted in a peptide (pT(502–510)) that binds 14-3-3ε with a K(D) value of 45.2 nM. Gly to Phe substitution in position 510 of pT(502–510) led to further improvement in affinity (K(D): 22.0 nM) of the peptide for 14-3-3ε. Our results suggest that the designed peptide analogs are potential candidates for inhibiting 14-3-3ε -CDC25A interactions in cSCC cells; thus, inducing their apoptosis.
format Online
Article
Text
id pubmed-10592926
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-105929262023-10-24 Optimizing Phosphopeptide Structures That Target 14-3-3ε in Cutaneous Squamous Cell Carcinoma Kamayirese, Seraphine Maity, Sibaprasad Dieckman, Lynne M. Hansen, Laura A. Lovas, Sándor bioRxiv Article 14-3-3ε is involved in various types of malignancies by increasing cell proliferation, promoting cell invasion or inhibiting apoptosis. In cutaneous squamous cell carcinoma (cSCC), 14-3-3ε is over expressed and mislocalized from the nucleus to the cytoplasm where it interacts with the cell division cycle 25 A (CDC25A) and suppresses apoptosis. Hence inhibition of the 14-3-3ε - CDC25A interaction is an attractive target for promoting apoptosis in cSCC. In this work, we optimized the structure of our previously designed inhibitor of 14-3-3ε – CDC25A interaction, pT, a phosphopeptide fragment corresponding to one of the two binding regions of CDC25A to 14-3-3ε. Starting from pT, we developed peptide analogs that bind 14-3-3ε with nanomolar affinities. Peptide analogs were designed by shortening the pT peptide, and introducing modifications at position 510 of the pT(502–510) analog. Both molecular dynamics (MD) simulations and biophysical methods were used to determine peptides binding to 14-3-3ε. Shortening the pT peptide from 14 to 9 amino acid residues resulted in a peptide (pT(502–510)) that binds 14-3-3ε with a K(D) value of 45.2 nM. Gly to Phe substitution in position 510 of pT(502–510) led to further improvement in affinity (K(D): 22.0 nM) of the peptide for 14-3-3ε. Our results suggest that the designed peptide analogs are potential candidates for inhibiting 14-3-3ε -CDC25A interactions in cSCC cells; thus, inducing their apoptosis. Cold Spring Harbor Laboratory 2023-10-03 /pmc/articles/PMC10592926/ /pubmed/37873379 http://dx.doi.org/10.1101/2023.10.03.560749 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Kamayirese, Seraphine
Maity, Sibaprasad
Dieckman, Lynne M.
Hansen, Laura A.
Lovas, Sándor
Optimizing Phosphopeptide Structures That Target 14-3-3ε in Cutaneous Squamous Cell Carcinoma
title Optimizing Phosphopeptide Structures That Target 14-3-3ε in Cutaneous Squamous Cell Carcinoma
title_full Optimizing Phosphopeptide Structures That Target 14-3-3ε in Cutaneous Squamous Cell Carcinoma
title_fullStr Optimizing Phosphopeptide Structures That Target 14-3-3ε in Cutaneous Squamous Cell Carcinoma
title_full_unstemmed Optimizing Phosphopeptide Structures That Target 14-3-3ε in Cutaneous Squamous Cell Carcinoma
title_short Optimizing Phosphopeptide Structures That Target 14-3-3ε in Cutaneous Squamous Cell Carcinoma
title_sort optimizing phosphopeptide structures that target 14-3-3ε in cutaneous squamous cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592926/
https://www.ncbi.nlm.nih.gov/pubmed/37873379
http://dx.doi.org/10.1101/2023.10.03.560749
work_keys_str_mv AT kamayireseseraphine optimizingphosphopeptidestructuresthattarget1433eincutaneoussquamouscellcarcinoma
AT maitysibaprasad optimizingphosphopeptidestructuresthattarget1433eincutaneoussquamouscellcarcinoma
AT dieckmanlynnem optimizingphosphopeptidestructuresthattarget1433eincutaneoussquamouscellcarcinoma
AT hansenlauraa optimizingphosphopeptidestructuresthattarget1433eincutaneoussquamouscellcarcinoma
AT lovassandor optimizingphosphopeptidestructuresthattarget1433eincutaneoussquamouscellcarcinoma